focus -WSS

focus

author：hotspot 2025-09-30 08:49:37 - browse：493

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： 7 more heat

WSS

Why Congress must ban federal programs from using QALYs

Regeneron agrees to White House price limits on anti

Judge rejects Trump's request to move Stormy Daniels hush

New Covid vaccine is recommended for everyone 6 months or older

EF3 tornado rips through North Carolina amid extreme weather nationwide

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

entertainment

focus

knowledge

At least 13 dead in Texas as scorching temps continue

Judge rejects Trump's request to move Stormy Daniels hush

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

What to make of Biden’s latest efforts on cancer research

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Stanford president faces new allegations over 1999 paper

Drug repurposing or repositioning? The language matters

How to make the FDA’s new prescription one

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Wikipedia

Study identifies new proteins linked to dementia risk 25 years later

How housing is health care on Long Island

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

Tesla recalling nearly 16,000 of its 2021

Hospitals struggle to profit from CAR

7 more heat

hotspot

focus

focus

leisure time